At Merck Frosst, patients come first. Merck Frosst Canada Ltd. is a research-driven pharmaceutical company. Merck Frosst discovers, develops and markets a broad range of innovative medicines to improve human health. The Merck Frosst Centre for Therapeutic Research, one of the largest biomedical research facilities in Canada, has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes, osteoporosis and hypertension. Merck Frosst is one of the top 20 R&D investors in Canada, with an investment of $114 million in 2006. The Company is committed to fostering partnerships to deliver the most valuable health outcomes for Canadian patients. Merck Frosst is a recognized leader in the treatment of asthma, osteoporosis, HIV/AIDS, glaucoma, prostate disease, migraines and infectious diseases. The Company also markets an extensive line of cardiovascular products for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines. Based in Montréal, Quebec, Merck Frosst employs nearly 1,600 people including more than 300 of the world's leading scientific personnel. It is also firmly committed to science education and sponsors a number of programs designed to spark young people's interest in science. More information about Merck Frosst is available at http://www.merckfrosst.com
DAWN GRAHAM, PRESIDENT
Adresse :
16711 TransCanada Highway
Kirkland, QC H9H 3L1
Canada
Numéro de téléphone :
514-428-2609
MERCK FROSST CANADA LTD. ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement